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Abstract
The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase
of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/
10.1111/bph.13352/full. Nuclear hormone receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ligand-gated
ion channels, voltage-gated ion channels, other ion channels, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best
available pharmacological tools, alongside key references and suggestions for further reading. The Concise Guide is published in landscape format in order to facilitate comparison of related targets.
It is a condensed version of material contemporary to late 2015, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data presented
in the previous Guides to Receptors & Channels and the Concise Guide to PHARMACOLOGY 2013/14. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification
and nomenclature for human drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR-DB and GRAC and provides a permanent, citable,
point-in-time record that will survive database updates.
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Overview: Nuclear hormone receptors are specialised transcrip-
tion factors with commonalities of sequence and structure, which
bind as homo- or heterodimers to specific consensus sequences
of DNA (response elements) in the promoter region of particu-
lar target genes. They regulate (either promoting or repressing)
transcription of these target genes in response to a variety of en-
dogenous ligands. Endogenous agonists are hydrophobic enti-
ties which, when bound to the receptor promote conformational
changes in the receptor to allow recruitment (or dissociation) of
protein partners, generating a large multiprotein complex.
Two major subclasses of nuclear receptors with identified endoge-
nous agonists can be identified: steroid and non-steroid hormone
receptors. Steroid hormone receptors function typically as dimeric
entities and are thought to be resident outside the nucleus in the
unliganded state in a complex with chaperone proteins, which
are liberated upon agonist binding. Migration to the nucleus and
interaction with other regulators of gene transcription, includ-
ing RNA polymerase, acetyltransferases and deacetylases, allows
gene transcription to be regulated. Non-steroid hormone recep-
tors typically exhibit a greater distribution in the nucleus in the
unliganded state and interact with other nuclear receptors to form
heterodimers, as well as with other regulators of gene transcrip-
tion, leading to changes in gene transcription upon agonist bind-
ing.
Selectivity of gene regulation is brought about through interac-
tion of nuclear receptors with particular consensus sequences of
DNA, which are arranged typically as repeats or inverted palin-
dromes to allow accumulation of multiple transcription factors in
the promoter regions of genes.
Searchable database: http://www.guidetopharmacology.org/index.jsp Nuclear hormone receptors 5956
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Family structure
5958 1A. Thyroid hormone receptors
5959 1B. Retinoic acid receptors
5960 1C. Peroxisome proliferator-activated receptors
5961 1D. Rev-Erb receptors
5962 1F. Retinoic acid-related orphans
5963 1H. Liver X receptor-like receptors
5964 1I. Vitamin D receptor-like receptors
5965 2A. Hepatocyte nuclear factor-4 receptors
5966 2B. Retinoid X receptors
5967 2C. Testicular receptors
5968 2E. Tailless-like receptors
5969 2F. COUP-TF-like receptors
5970 3B. Estrogen-related receptors
5971 4A. Nerve growth factor IB-like receptors
5972 5A. Fushi tarazu F1-like receptors
5973 6A. Germ cell nuclear factor receptors
5974 0B. DAX-like receptors
5975 Steroid hormone receptors
5975 3A. Estrogen receptors
5976 3C. 3-Ketosteroid receptors
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1A. Thyroid hormone receptors
Nuclear hormone receptors! 1A. Thyroid hormone receptors
Overview: Thyroid hormone receptors (TRs, nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [41]) are nuclear hormone receptors of the NR1A
family, with diverse roles regulating macronutrient metabolism, cognition and cardiovascular homeostasis. TRs are activated by thyroxine (T4) and thyroid hormone (triiodothyronine). Once activated
by a ligand, the receptor acts as a transcription factor either as a monomer, homodimer or heterodimer with members of the retinoid X receptor family. NH-3 has been described as an antagonist at TRs
with modest selectivity for TRβ [111].
Nomenclature Thyroid hormone receptor-α Thyroid hormone receptor-β
Systematic nomenclature NR1A1 NR1A2
HGNC, UniProt THRA, P10827 THRB, P10828
Rank order of potency triiodothyronine> T4 triiodothyronine> T4
Agonists dextrothyroxine [20] dextrothyroxine [20]
Selective agonists – sobetirome (pKd 10.2) [27, 133]
Comments: An interaction with integrin αVβ3 has been suggested to underlie plasma membrane localization of TRs and non-genomic signalling [9].One splice variant, TRα2, lacks a functional DNA-
binding domain and appears to act as a transcription suppressor.
Although radioligand binding assays have been described for these receptors, the radioligands are not commercially available.
Further Reading
Bianco AC. (2011) Minireview: cracking the metabolic code for thyroid hormone signaling. En-
docrinology 152: 3306-11 [PMID:21712363]
Brent GA. (2012) Mechanisms of thyroid hormone action. J. Clin. Invest. 122: 3035-43
[PMID:22945636]
Flamant F et al. (2006) International Union of Pharmacology. LIX. The pharmacology and classi-
fication of the nuclear receptor superfamily: thyroid hormone receptors. Pharmacol. Rev. 58:
705-11 [PMID:17132849]
Pramfalk C et al. (2011) Role of thyroid receptor β in lipid metabolism. Biochim. Biophys. Acta 1812:
929-37 [PMID:21194564]
Sirakov M et al. (2011) The thyroid hormones and their nuclear receptors in the gut: from develop-
mental biology to cancer. Biochim. Biophys. Acta 1812: 938-46 [PMID:21194566]
Tancevski I et al. (2011) Thyromimetics: a journey from bench to bed-side. Pharmacol. Ther. 131:
33-9 [PMID:21504761]
Searchable database: http://www.guidetopharmacology.org/index.jsp Thyroid hormone receptors 5958
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1B. Retinoic acid receptors
Nuclear hormone receptors! 1B. Retinoic acid receptors
Overview: Retinoic acid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [46]) are nuclear hormone receptors of the NR1B family
activated by the vitamin A-derived agonists tretinoin (ATRA) and alitretinoin, and the RAR-selective synthetic agonists TTNPB and adapalene. BMS493 is a family-selective antagonist [47].
Nomenclature Retinoic acid receptor-α Retinoic acid receptor-β Retinoic acid receptor-γ
Systematic nomenclature NR1B1 NR1B2 NR1B3
HGNC, UniProt RARA, P10276 RARB, P10826 RARG, P13631
Agonists tretinoin (pEC50 7.8) [26] tretinoin (pEC50 7.9) [26] tretinoin (pEC50 9.7) [26]
(Sub)family-selective agonists tazarotene (pEC50 7.2) [26] tazarotene (pEC50 9.1) [26], adapalene
(pKi 7.5) [25]
tazarotene (pEC50 7.4) [26], adapalene
(pKi 6.9) [25]
Selective agonists BMS753 (pKi 8.7) [53], Ro 40-6055 (pKd 8.2)
[33], tamibarotene (pIC50 6.9) [65, 108, 146]
AC261066 (pEC50 7.9–8.1) [90], AC55649
(pEC50 6.5–7.3) [90]
AHPN (pKi 7.1) [25]
Selective antagonists Ro 41-5253 (pIC50 6.3–7.2) [2, 70] – MM 11253 [77]
Comments: Ro 41-5253 has been suggested to be a PPARγ agonist [131]. LE135 is an antagonist with selectivity for RARα and RARβ compared with RARγ [85].
Further Reading
Bour G et al. (2007) Protein kinases and the proteasome join in the combinatorial control of tran-
scription by nuclear retinoic acid receptors. Trends Cell Biol. 17: 302-9 [PMID:17467991]
Duong V et al. (2011) The molecular physiology of nuclear retinoic acid receptors. From health to
disease. Biochim. Biophys. Acta 1812: 1023-31 [PMID:20970498]
Germain P et al. (2006) International Union of Pharmacology. LX. Retinoic acid receptors. Pharma-
col. Rev. 58: 712-25 [PMID:17132850]
Maden M. (2007) Retinoic acid in the development, regeneration and maintenance of the nervous
system. Nat. Rev. Neurosci. 8: 755-65 [PMID:17882253]
Mark M et al. (2006) Function of retinoid nuclear receptors: lessons from genetic and pharmacolog-
ical dissections of the retinoic acid signaling pathway during mouse embryogenesis. Annu. Rev.
Pharmacol. Toxicol. 46: 451-80 [PMID:16402912]
Searchable database: http://www.guidetopharmacology.org/index.jsp Retinoic acid receptors 5959
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1C. Peroxisome proliferator-activated receptors
Nuclear hormone receptors! 1C. Peroxisome proliferator-activated receptors
Overview: Peroxisome proliferator-activated receptors (PPARs,
nomenclature as agreed by the NC-IUPHAR Subcommit-
tee on Nuclear Hormone Receptors [101]) are nuclear hor-
mone receptors of the NR1C family, with diverse roles regulat-
ing lipid homeostasis, cellular differentiation, proliferation and
the immune response. PPARs have many potential endoge-
nous agonists [14, 101], including 15-deoxy-112,14-PGJ2, prosta-
cyclin (PGI2), many fatty acids and their oxidation products,
lysophosphatidic acid (LPA) [98], 13-HODE, 15S-HETE, Paz-PC,
azelaoyl-PAF and leukotriene B4 (LTB4). Bezafibrate acts as a
non-selective agonist for the PPAR family [159]. These recep-
tors also bind hypolipidaemic drugs (PPARα) and anti-diabetic
thiazolidinediones (PPARγ), as well as many non-steroidal anti-
inflammatory drugs, such as sulindac and indomethacin. Once
activated by a ligand, the receptor forms a heterodimer withmem-
bers of the retinoid X receptor family and can act as a transcription
factor. Although radioligand binding assays have been described
for all three receptors, the radioligands are not commercially avail-
able. Commonly, receptor occupancy studies are conducted using
fluorescent ligands and truncated forms of the receptor limited to
the ligand binding domain.
Nomenclature Peroxisome proliferator-activated receptor-α Peroxisome proliferator-activated receptor-β/Æ Peroxisome proliferator-activated receptor-γ
Systematic nomenclature NR1C1 NR1C2 NR1C3
HGNC, UniProt PPARA, Q07869 PPARD, Q03181 PPARG, P37231
Agonists – – mesalazine (pIC50 1.8) [126]
Selective agonists GW7647 (pEC50 8.2) [18, 19], CP-775146
(pEC50 7.3) [68], pirinixic acid (pEC50 5.3)
[159], gemfibrozil (pEC50 4.2) [31],
ciprofibrate
GW0742X (pIC50 9) [50, 144], GW501516
(pEC50 9) [113]
GW1929 (pKi 8.8) [18], bardoxolone (Partial
agonist) (pKi 8) [153], rosiglitazone (pKd 7.4) [59,
81, 165], rosiglitazone (pKi 6.9) [88], troglitazone
(pIC50 6.3) [59, 165], pioglitazone (pIC50 6.2) [59,
129, 165], troglitazone (pKi 5.8) [8], ciglitazone
(pEC50 4.6) [59]
Selective antagonists GW6471 (pIC50 6.6) [162] GSK0660 (pIC50 6.5) [134] T0070907 (pKi 9) [78], GW9662 (Irreversible
inhibition) (pIC50 8.1) [79], CDDO-Me (pKi 6.9)
[153]
Comments: As with the estrogen receptor antagonists, many agents show tissue-selective efficacy (e.g. [13, 110, 125]). Agonists with mixed activity at PPARα and PPARγ have also been described (e.g [35,
52, 163]).
Further Reading
Huang JV et al. (2012) PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncer-
tainty. J. Lipid Res. 53: 1738-54 [PMID:22685322]
Michalik L et al. (2006) International Union of Pharmacology. LXI. Peroxisome proliferator-activated
receptors. Pharmacol. Rev. 58: 726-41 [PMID:17132851]
Michalik L et al. (2008) PPARs Mediate Lipid Signaling in Inflammation and Cancer. PPAR Res 2008:
134059 [PMID:19125181]
Peters JM et al. (2012) The role of peroxisome proliferator-activated receptors in carcinogenesis and
chemoprevention. Nat. Rev. Cancer 12: 181-95 [PMID:22318237]
Pirat C et al. (2012) Targeting peroxisome proliferator-activated receptors (PPARs): development of
modulators. J. Med. Chem. 55: 4027-61 [PMID:22260081]
Varga T et al. (2011) PPARs are a unique set of fatty acid regulated transcription factors con-
trolling both lipid metabolism and inflammation. Biochim. Biophys. Acta 1812: 1007-22
[PMID:21382489]
Youssef J et al. (2011) Peroxisome proliferator-activated receptors and cancer: challenges and oppor-
tunities. Br. J. Pharmacol. 164: 68-82 [PMID:21449912]
Searchable database: http://www.guidetopharmacology.org/index.jsp Peroxisome proliferator-activated receptors 5960
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1D. Rev-Erb receptors
Nuclear hormone receptors! 1D. Rev-Erb receptors
Overview: Rev-erb receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [7]) have yet to be officially paired with an endogenous ligand,
but are thought to be activated by heme.
Nomenclature Rev-Erb-α Rev-Erb-β
Systematic nomenclature NR1D1 NR1D2
HGNC, UniProt NR1D1, P20393 NR1D2, Q14995
Endogenous agonists heme (Selective) [122, 164] heme (Selective) [122, 164]
Selective agonists GSK4112 (pEC50 6.4) [51], GSK4112 (pIC50 5.6) [73] –
Selective antagonists SR8278 (pIC50 6.5) [73] –
Further Reading
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Phar-
macol. Rev. 58: 798-836 [PMID:17132856]
Duez H et al. (2009) Rev-erb-alpha: an integrator of circadian rhythms and metabolism. J. Appl.
Physiol. 107: 1972-80 [PMID:19696364]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685-704
[PMID:17132848]
Huang P et al. (2010) Structural overview of the nuclear receptor superfamily: insights into physiol-
ogy and therapeutics. Annu. Rev. Physiol. 72: 247-72 [PMID:20148675]
Phelan CA et al. (2010) Structure of Rev-erbalpha bound to N-CoR reveals a unique mechanism of
nuclear receptor-co-repressor interaction. Nat. Struct. Mol. Biol. 17: 808-14 [PMID:20581824]
Sladek FM. (2011) What are nuclear receptor ligands? Mol. Cell. Endocrinol. 334: 3-13
[PMID:20615454]
Yin L et al. (2010) Nuclear receptor Rev-erbalpha: a heme receptor that coordinates circadian rhythm
and metabolism. Nucl Recept Signal 8: e001 [PMID:20414452]
Searchable database: http://www.guidetopharmacology.org/index.jsp Rev-Erb receptors 5961
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1F. Retinoic acid-related orphans
Nuclear hormone receptors! 1F. Retinoic acid-related orphans
Overview: Retinoic acid receptor-related orphan receptors (ROR, nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [7]) have yet to be assigned a
definitive endogenous ligand, although RORα may be synthesized with a ‘captured’ agonist such as cholesterol [66, 67].
Nomenclature RAR-related orphan receptor-α RAR-related orphan receptor-β RAR-related orphan receptor-γ
Systematic nomenclature NR1F1 NR1F2 NR1F3
HGNC, UniProt RORA, P35398 RORB, Q92753 RORC, P51449
Endogenous agonists cholesterol (Selective) [67, 115] – –
Selective agonists 7-hydroxycholesterol [15],
cholesterol sulphate [15, 67]
– –
Comments: tretinoin shows selectivity for RORβ within the ROR family [139]. RORα has been suggested to be a nuclear receptor responding to melatonin [158].
Further Reading
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol. Rev. 58: 798-836 [PMID:17132856]
Searchable database: http://www.guidetopharmacology.org/index.jsp Retinoic acid-related orphans 5962
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1H. Liver X receptor-like receptors
Nuclear hormone receptors! 1H. Liver X receptor-like receptors
Overview: Liver X and farnesoid X receptors (LXR and FXR, nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [105]) are members of a steroid
analogue-activated nuclear receptor subfamily, which form heterodimers with members of the retinoid X receptor family. Endogenous ligands for LXRs include hydroxycholesterols (OHC), while FXRs
appear to be activated by bile acids.
Nomenclature Farnesoid X receptor Farnesoid X receptor-β Liver X receptor-α Liver X receptor-β
Systematic nomenclature NR1H4 NR1H5 NR1H3 NR1H2
HGNC, UniProt NR1H4, Q96RI1 NR1H5P, – NR1H3, Q13133 NR1H2, P55055
Potency order chenodeoxycholic acid >
lithocholic acid, deoxycholic acid
[93, 116]
– 20S-hydroxycholesterol,
22R-hydroxycholesterol,
24(S)-hydroxycholesterol >
25-hydroxycholesterol,
27-hydroxycholesterol [80]
20S-hydroxycholesterol,
22R-hydroxycholesterol,
24(S)-hydroxycholesterol >
25-hydroxycholesterol,
27-hydroxycholesterol [80]
Endogenous agonists – lanosterol (pEC50 6) [114] –
Mouse
– –
Selective agonists GW4064 (pEC50 7.8) [95],
obeticholic acid (pEC50 7) [117],
fexaramine (pEC50 6.6) [36]
– – –
Selective antagonists guggulsterone (pIC50 5.7–6) [161] – – –
Comments: T0901317 [123] and GW3965 [28] are synthetic agonists acting at both LXRα and LXRβ with less than 10-fold selectivity.
Further Reading
A-González N et al. (2011) Liver X receptors as regulators ofmacrophage inflammatory andmetabolic
pathways. Biochim. Biophys. Acta 1812: 982-94 [PMID:21193033]
Calkin AC et al. (2010) Liver x receptor signaling pathways and atherosclerosis. Arterioscler. Thromb.
Vasc. Biol. 30: 1513-8 [PMID:20631351]
Chen WD et al. (2011) Nuclear bile acid receptor FXR in the hepatic regeneration. Biochim. Biophys.
Acta 1812: 888-92 [PMID:21167938]
Claudel T et al. (2011) Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis,
and gallstone disease. Biochim. Biophys. Acta 1812: 867-78 [PMID:21194565]
El-Hajjaji FZ et al. (2011) Liver X receptors, lipids and their reproductive secrets in the male. Biochim.
Biophys. Acta 1812: 974-81 [PMID:21334438]
Gadaleta RM et al. (2010) Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and
gastrointestinal disease. Biochim. Biophys. Acta 1801: 683-92 [PMID:20399894]
GardmoC et al. (2011) Proteomics for the discovery of nuclear bile acid receptor FXR targets. Biochim.
Biophys. Acta 1812: 836-41 [PMID:21439373]
Kemper JK. (2011) Regulation of FXR transcriptional activity in health and disease: Emerging roles
of FXR cofactors and post-translational modifications. Biochim. Biophys. Acta 1812: 842-50
[PMID:21130162]
Matsubara T et al. (2013) FXR signaling in the enterohepatic system. Mol. Cell. Endocrinol. 368:
17-29 [PMID:22609541]
Moore DD et al. (2006) International Union of Pharmacology. LXII. The NR1H and NR1I receptors:
constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X
receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol.
Rev. 58: 742-59 [PMID:17132852]
Searchable database: http://www.guidetopharmacology.org/index.jsp Liver X receptor-like receptors 5963
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1I. Vitamin D receptor-like receptors
Nuclear hormone receptors! 1I. Vitamin D receptor-like receptors
Overview: Vitamin D (VDR), Pregnane X (PXR) and Constitutive Androstane (CAR) receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors
[105]) are members of the NR1I family of nuclear receptors, which form heterodimers with members of the retinoid X receptor family. PXR and CAR are activated by a range of exogenous compounds,
with no established endogenous physiological agonists, although high concentrations of bile acids and bile pigments activate PXR and CAR [105].
Nomenclature Vitamin D receptor Pregnane X receptor Constitutive androstane receptor
Systematic nomenclature NR1I1 NR1I2 NR1I3
HGNC, UniProt VDR, P11473 NR1I2, O75469 NR1I3, Q14994
Endogenous agonists 1,25-dihydroxyvitamin D3 (pKd 8.9–9.2) [12, 39] 17β-estradiol (Selective) [64] –
Selective agonists seocalcitol (pKd 9.6) [29, 157], doxercalciferol hyperforin (pEC50 7.6) [106, 156],
5β-pregnane-3,20-dione (pIC50 6.4) [64],
lovastatin (pEC50 5.3–6) [82], rifampicin
(pEC50 5.5–6) [16, 82]
TCPOBOP (pEC50 7.7) [149] – Mouse,
CITCO (pEC50 7.3) [92]
Selective antagonists TEI-9647 (pIC50 8.2) [128] – Chicken, ZK159222
(pIC50 7.5) [42, 60]
– –
Comments – – clotrimazole [107] and T0901317 [69]
although acting at other sites, function as
antagonists of the constitutive androstane
receptor.
Further Reading
Bikle DD. (2011) Vitamin D: an ancient hormone. Exp. Dermatol. 20: 7-13 [PMID:21197695]
Campbell FC et al. (2010) The yin and yang of vitamin D receptor (VDR) signaling in neoplastic
progression: operational networks and tissue-specific growth control. Biochem. Pharmacol. 79:
1-9 [PMID:19737544]
Chen Y et al. (2012) Nuclear receptors in the multidrug resistance through the regulation
of drug-metabolizing enzymes and drug transporters. Biochem. Pharmacol. 83: 1112-26
[PMID:22326308]
Cheng J et al. (2012) Pregnane X receptor as a target for treatment of inflammatory bowel disorders.
Trends Pharmacol. Sci. 33: 323-30 [PMID:22609277]
Ihunnah CA et al. (2011) Nuclear receptor PXR, transcriptional circuits and metabolic relevance.
Biochim. Biophys. Acta 1812: 956-63 [PMID:21295138]
Kachaylo EM et al. (2011) Constitutive androstane receptor (CAR) is a xenosensor and target for
therapy. Biochemistry Mosc. 76: 1087-97 [PMID:22098234]
Moore DD et al. (2006) International Union of Pharmacology. LXII. The NR1H and NR1I receptors:
constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X
receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor. Pharmacol.
Rev. 58: 742-59 [PMID:17132852]
Plum LA et al. (2010) Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov 9:
941-55 [PMID:21119732]
Staudinger JL et al. (2013) Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter
proteins in gut and liver. Drug Metab. Rev. 45: 48-59 [PMID:23330541]
Searchable database: http://www.guidetopharmacology.org/index.jsp Vitamin D receptor-like receptors 5964
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13352/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. British Journal of Pharmacology (2015) 172, 5956–5978
2A. Hepatocyte nuclear factor-4 receptors
Nuclear hormone receptors! 2A. Hepatocyte nuclear factor-4 receptors
Overview: The nomenclature of hepatocyte nuclear factor-4 receptors is agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [7]. While linoleic acid has been identified as
the endogenous ligand for HNF4α its function remains ambiguous [167]. HNF4γ has yet to be paired with an endogenous ligand.
Nomenclature Hepatocyte nuclear factor-4-α Hepatocyte nuclear factor-4-γ
Systematic nomenclature NR2A1 NR2A2
HGNC, UniProt HNF4A, P41235 HNF4G, Q14541
Endogenous agonists linoleic acid (Selective) [167] –
Selective antagonists BI6015 [72] –
Comments HNF4α has constitutive transactivation activity [167] and
binds DNA as a homodimer [63].
–
Further Reading
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Phar-
macol. Rev. 58: 798-836 [PMID:17132856]
Germain P et al. (2006) Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 58: 685-704
[PMID:17132848]
Huang P et al. (2010) Structural overview of the nuclear receptor superfamily: insights into physiol-
ogy and therapeutics. Annu. Rev. Physiol. 72: 247-72 [PMID:20148675]
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2B. Retinoid X receptors
Nuclear hormone receptors! 2B. Retinoid X receptors
Overview: Retinoid X receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [45]) are NR2B family members activated by alitretinoin and
the RXR-selective agonists bexarotene and LG100268, sometimes referred to as rexinoids. UVI3003 [109] and HX 531 [37] have been described as a pan-RXR antagonists. These receptors form RXR-RAR
heterodimers and RXR-RXR homodimers [23, 97].
Nomenclature Retinoid X receptor-α Retinoid X receptor-β Retinoid X receptor-γ
Systematic nomenclature NR2B1 NR2B2 NR2B3
HGNC, UniProt RXRA, P19793 RXRB, P28702 RXRG, P48443
(Sub)family-selective agonists bexarotene (pIC50 7.4) [17, 22, 146] bexarotene (pIC50 7.7) [17, 22, 146] bexarotene (pIC50 7.5) [17, 22, 146]
Selective agonists CD3254 (pIC50 8.5) [48] – –
Further Reading
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2C. Testicular receptors
Nuclear hormone receptors! 2C. Testicular receptors
Overview: Testicular receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [7]) have yet to be officially paired with an endogenous ligand,
although testicular receptor 4 has been reported to respond to retinoids.
Nomenclature Testicular receptor 2 Testicular receptor 4
Systematic nomenclature NR2C1 NR2C2
HGNC, UniProt NR2C1, P13056 NR2C2, P49116
Endogenous agonists – retinol (Selective) [173], tretinoin (Selective) [173]
Comments Forms a heterodimer with TR4; gene disruption appears without
effect on testicular development or function [135].
Forms a heterodimer with TR2.
Further Reading
Benoit G et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Phar-
macol. Rev. 58: 798-836 [PMID:17132856]
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2E. Tailless-like receptors
Nuclear hormone receptors! 2E. Tailless-like receptors
Overview: Tailless-like receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [7]) have yet to be officially paired with an endogenous ligand.
Nomenclature TLX PNR
Systematic nomenclature NR2E1 NR2E3
HGNC, UniProt NR2E1, Q9Y466 NR2E3, Q9Y5X4
Comments Gene disruption is associated with abnormal brain development [76, 104]. –
Further Reading
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2F. COUP-TF-like receptors
Nuclear hormone receptors! 2F. COUP-TF-like receptors
Overview: COUP-TF-like receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [7]) have yet to be officially paired with an endogenous
ligand.
Nomenclature COUP-TF1 COUP-TF2 V-erbA-related gene
Systematic nomenclature NR2F1 NR2F2 NR2F6
HGNC, UniProt NR2F1, P10589 NR2F2, P24468 NR2F6, P10588
Comments Gene disruption is perinatally lethal [121]. Gene disruption is embryonically lethal [118]. Gene disruption impairs CNS development [155].
Further Reading
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3B. Estrogen-related receptors
Nuclear hormone receptors! 3B. Estrogen-related receptors
Overview: Estrogen-related receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [7]) have yet to be officially paired with an endogenous
ligand.
Nomenclature Estrogen-related receptor-α Estrogen-related receptor-β Estrogen-related receptor-γ
Systematic nomenclature NR3B1 NR3B2 NR3B3
HGNC, UniProt ESRRA, P11474 ESRRB, O95718 ESRRG, P62508
Comments Activated by some dietary flavonoids [141];
activated by the syntheticagonist GSK4716
[176] and blocked by XCT790 [160].
May be activated by DY131 [166]. May be activated by DY131 [166].
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4A. Nerve growth factor IB-like receptors
Nuclear hormone receptors! 4A. Nerve growth factor IB-like receptors
Overview: Nerve growth factor IB-like receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [7]) have yet to be officially paired with an
endogenous ligand.
Nomenclature Nerve Growth factor IB Nuclear receptor related 1 Neuron-derived orphan receptor 1
Systematic nomenclature NR4A1 NR4A2 NR4A3
HGNC, UniProt NR4A1, P22736 NR4A2, P43354 NR4A3, Q92570
Comments An endogenous agonist, cytosporone B, has been described
[168], although structural analysis and molecular modelling
has not identified a ligand binding site [4, 40, 154].
– –
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5A. Fushi tarazu F1-like receptors
Nuclear hormone receptors! 5A. Fushi tarazu F1-like receptors
Overview: Fushi tarazu F1-like receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [7]) have yet to be officially paired with an endogenous
ligand.
Nomenclature Steroidogenic factor 1 Liver receptor homolog-1
Systematic nomenclature NR5A1 NR5A2
HGNC, UniProt NR5A1, Q13285 NR5A2, O00482
Comments Reported to be inhibited by AC45594 [32] and SID7969543 [91]. –
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6A. Germ cell nuclear factor receptors
Nuclear hormone receptors! 6A. Germ cell nuclear factor receptors
Overview: Germ cell nuclear factor receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [7]) have yet to be officially paired with an
endogenous ligand.
Nomenclature Germ cell nuclear factor
Systematic nomenclature NR6A1
HGNC, UniProt NR6A1, Q15406
Further Reading
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0B. DAX-like receptors
Nuclear hormone receptors! 0B. DAX-like receptors
Overview: Dax-like receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors [7]) have yet to be officially paired with an endogenous ligand.
Nomenclature DAX1 SHP
Systematic nomenclature NR0B1 NR0B2
HGNC, UniProt NR0B1, P51843 NR0B2, Q15466
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Steroid hormone receptors
Nuclear hormone receptors! Steroid hormone receptors
Overview: Steroid hormone receptors (nomenclature as
agreed by the NC-IUPHAR Subcommittee onNuclearHor-
mone Receptors [30, 89]) are nuclear hormone receptors of the
NR3 class, with endogenous agonists that may be divided into
3-hydroxysteroids (estrone and 17β-estradiol) and 3-ketosteroids
(dihydrotestosterone [DHT], aldosterone, cortisol, corticosterone,
progesterone and testosterone). These receptors exist as dimers
coupled with chaperone molecules (such as hsp90β ( HSP90AB1,
P08238) and immunophilin FKBP52:FKBP4, Q02790), which are
shed on binding the steroid hormone. Although rapid signalling
phenomena are observed [84, 120], the principal signalling cas-
cade appears to involve binding of the activated receptors to
nuclear hormone response elements of the genome, with a 15-
nucleotide consensus sequence AGAACAnnnTGTTCT (i.e. an in-
verted palindrome) as homo- or heterodimers. They also affect
transcription by protein-protein interactions with other transcrip-
tion factors, such as activator protein 1 (AP-1) and nuclear fac-
tor B (NF-B). Splice variants of each of these receptors can form
functional or non-functionalmonomers that can dimerize to form
functional or non-functional receptors. For example, alternative
splicing of PR mRNA produces A and B monomers that combine
to produce functional AA, AB and BB receptors with distinct char-
acteristics [150].
A 7TM receptor responsive to estrogen (GPER1, Q99527, also
known as GPR30, see [119]) has been described. Human ortho-
logues of 7TM ’membrane progestin receptors’ (PAQR7, PAQR8
and PAQR5), initially discovered in fish [174, 175], appear to lo-
calize to intracellular membranes and respond to ’non-genomic’
progesterone analogues independently of G proteins [137].
3A. Estrogen receptors
Nuclear hormone receptors! Steroid hormone receptors! 3A. Estrogen receptors
Overview: Estrogen receptor (ER) activity regulates diverse physiological processes via transcriptional modulation of target genes. The selection of target genes and the magnitude of the response, be it
induction or repression, are determined by many factors, including the effect of the hormone ligand and DNA binding on ER structural conformation, and the local cellular regulatory environment. The
cellular environment defines the specific complement of DNA enhancer and promoter elements present and the availability of coregulators to form functional transcription complexes. Together, these
determinants control the resulting biological response.
Nomenclature Estrogen receptor-α Estrogen receptor-β
Systematic nomenclature NR3A1 NR3A2
HGNC, UniProt ESR1, P03372 ESR2, Q92731
Endogenous agonists estriol (pKi 8.7) [75], estrone (pKi 8.5) [75] –
Selective agonists propylpyrazoletriol (pKi 9.6) [74, 138], ethinyl estradiol (pIC50 8.7)
[62]
WAY200070 (pIC50 8.5–9) [94], diarylpropionitril (pKi 8.6) [100, 138],
prinaberel (pIC50 8.3) [94]
(Sub)family-selective antagonists bazedoxifene (pIC50 7.6) [103] bazedoxifene (pIC50 7.1) [103]
Selective antagonists clomiphene (pKi 8.9) [3], methyl-piperidino-pyrazole (pKi 8.6) [142] R,R-THC (pKi 8.4) [99, 143], PHTPP (pKi 6.9) [172]
Comments: R,R-THC exhibits partial agonist activity at ERα
[99, 143]. Estrogen receptors may be blocked non-selectively by
tamoxifen and raloxifene and labelled by [3H]17β-estradiol and
[3H]tamoxifen. Many agents thought initially to beantagonists
at estrogen receptors appear to have tissue-specific efficacy (e.g.
Tamoxifen is an antagonist at estrogen receptors in the breast,
but is an agonist at estrogen receptors in the uterus), hence
the descriptor SERM (selective estrogen receptor modulator) or
SnuRM (selective nuclear receptormodulator). Y134 has been sug-
gested to be an ERα-selective estrogen receptor modulator [112].
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3C. 3-Ketosteroid receptors
Nuclear hormone receptors! Steroid hormone receptors! 3C. 3-Ketosteroid receptors
Nomenclature Androgen receptor Glucocorticoid receptor Mineralocorticoid receptor Progesterone receptor
Systematic nomenclature NR3C4 NR3C1 NR3C2 NR3C3
HGNC, UniProt AR, P10275 NR3C1, P04150 NR3C2, P08235 PGR, P06401
Rank order of potency dihydrotestosterone >
testosterone
cortisol, corticosterone
aldosterone, deoxycortisone
[127]
corticosterone, cortisol,
aldosterone, progesterone [127]
progesterone
Endogenous agonists dihydrotestosterone (pKd 9.3)
[147]
– aldosterone (Selective) (pIC50
9.8–10) [58, 127]
progesterone (Selective) (pEC50
8.8) [38]
Agonists methyltestosterone (Androgen
receptor promoter activity in
luciferase reporter assay) (pEC50
9.7) [1], danazol (pKi 8) [24] –
Rat, ethylestrenol, nandrolone
– – –
Selective agonists testosterone propionate (pKi
9.6) [96], mibolerone (pIC50 9)
[49], fluoxymesterone (pKi 8.2)
[61], methyltrienolone (pEC50
<5) [152],
dromostanolone propionate
fluticasone propionate (pIC50
9.3) [11], clobetasol propionate
(pKi 9.2) [3], desoximetasone
(pKi 8.9) [3], fluorometholone
(pKi 8.8) [3], flunisolide (pKi 8.6)
[3], diflorasone diacetate (pKi
8.5) [3], fluocinolone acetonide
(pIC50 8.5) [3], beclometasone
(pKi 8.4) [3],
methylprednisolone (pKi 8.3)
[3], fluocinonide (pIC50 8.3) [3],
betamethasone (pIC50 8.1) [3],
budesonide (pEC50 7.9) [102],
triamcinolone (pIC50 7.7) [87],
ZK216348 (pIC50 7.7) [132],
ciclesonide (pKi 7.4) [6],
prednisone (pKi 6.3) [3],
RU26988 – Unknown, RU28362,
difluprednate [145], fluticasone
– medroxyprogesterone (Affinity at
human PR-A) (pKi 9.5) [170],
ORG2058, levonorgestrel [10,
130]
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(continued)
Nomenclature Androgen receptor Glucocorticoid receptor Mineralocorticoid receptor Progesterone receptor
Antagonists cyproterone acetate (pKi 7.8)
[55]
mifepristone (pKd 9.4) [57, 127] nimodipine (inhibition of
aldosterone-induced luciferase
activity in a reporter system
driven by the mineralocorticoid
receptor ligand binding domain)
(pIC50 6.8) [34]
–
Selective antagonists bicalutamide (pKi 7.7) [71],
PF0998425 (pIC50 7.1–7.5) [86],
enzalutamide (pIC50 7.4) [148],
nilutamide (pIC50 7.1–7.1) [136],
hydroxyflutamide (pEC50 6.6)
[152], galeterone (pIC50 6.4)
[56], flutamide (Displacement of
3[H] testosterone from wild-type
androgen receptors) (pKi 5.4)
[151]
onapristone (pIC50 7.6) [169],
ZK112993
finerenone (pIC50 7.7) [21],
eplerenone (pKi 6.9) [5],
onapristone (pIC50 6.3) [169],
RU28318, ZK112993
ulipristal acetate (pIC50 9.7)
[124], mifepristone (Mixed) (pKi
9) [171], onapristone (pKi 7.7)
[54], ZK112993
Labelled ligands [3H]dihydrotestosterone
(Selective Agonist),
[3H]methyltrienolone (Selective
Agonist), [3H]mibolerone
(Agonist)
[3H]dexamethasone (Agonist) [3H]aldosterone (Selective
Agonist) (pKd 9.5–9.4) [44, 140]
– Rat
[3H]ORG2058 (Selective
Agonist)
Comments: [3H]dexamethasone also binds to MRin vitro. PR antagonists have been suggested to subdivide into Type I (e.g. onapristone) and Type II (e.g. ZK112993) groups. These groups appear to
promote binding of PR to DNA with different efficacies and evoke distinct conformational changes in the receptor, leading to a transcription-neutral complex [43, 83]. Mutations in AR underlie testicular
feminization and androgen insensibility syndromes, spinal and bulbar muscular atrophy (Kennedy’s disease).
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